Search Blog
Categories
May 2018
M T W T F S S
« Apr    
 123456
78910111213
14151617181920
21222324252627
28293031  

Tags

Coronet Metals Inc. Acquires Critical Mass Land Position in Meguma Gold Belt

Vancouver, British Columbia–(Newsfile Corp. – May 18, 2018) – Coronet Metals Inc. (TSXV: CRF) (FSE: 2CM) (OTC Pink: CORMF) (the “Company”) is pleased to announce that it has entered into an agreement that will allow the company to gain a 100% interest in a large land position in one of Canada’s historic gold districts. The Company will acquire 3,888 mineral claims totalling over 62,000 hectares becoming one of the provinces largest single mineral claim holders and a leading gold exploration company in Nova Scotia. These claims were staked along the under-explored trends of known gold producing anticlinal structures and the Company estimates that it will control approximately 242 km (total strike length) of gold-prospective anticlines.

Through this acquisition the Company believes it has a unique opportunity to control the largest strike-length share of projected anticlines in the province and will employ state of the art clean technology exploration that will assess the true gold potential. In order to better define these anticlinal trends, and to focus an aggressive Phase 1 exploration program, the company has initiated a 12,342 kilometre aeromagnetic and radiometric survey along with a 1,110 square kilometres of LiDAR survey.

Mr. Theo van der Linde, President of the Company stated: “The awakening of Nova Scotia’s gold fields due to a recognition that an economic disseminated gold exploration and production model exists in the Meguma gold belt offers our shareholders a rare opportunity to participate in a regional-scale gold exploration platform. On behalf of shareholders, I extend my appreciation to Coronet’s talented technical team who have helped to position our company with this exciting project.

Nova Scotia — A Gold-Rich Past and Future

Nova Scotia has a rich history of gold discovery and production, and has been one of Canada’s first gold mining camps with production dating back to 1861. Between 1862 and 1927, 966,241 ounces of gold were mined from 2,184,850 tons of crushed material (G. Malcolm 1929 Memoir). Historic exploration has focused on narrow vein high-grade gold deposits but the discovery in the 1980’s of significant disseminated gold within argillite shales at the Touquoy deposit, and the opening of a new mine by Atlantic Gold has renewed interest in Nova Scotia’s historic gold districts.

The Company’s mineral claims are adjacent and along trend from Atlantic Gold’s Touquoy disseminated open-pit gold deposit. Atlantic Gold has outlined a Measured plus Indicated resource of 10.1 million tonnes grading 1.5 gram per tonne for a total of 480,000 ounces of gold, plus an inferred resource of 1.6 million tonnes and 77,000 ounces of gold (Atlantic Gold, August 2014).

Please Click on Link Below for Map

http://www.coronetmetals.com/meguma-gold.html

Upcoming Exploration Work

In conjunction with this new project acquisition, the Company has initiated a multi-phase exploration program aimed at defining and drill testing numerous targets moving-forward. Phase 1 exploration will include:

  • A detailed (100 metre line spacing) 12,000 km airborne geophysics and LiDAR program which is one of the largest modern-day airborne initiatives in Nova Scotia.
  • Re-interpretation of past geophysical work of known deposits to develop a proprietary “fingerprint” model for identifying new deposits within the project.
  • Reprocessing and modeling of new aeromagnetic, radiometrics and LiDAR.
  • Development of a 3D prospectively model identify geology, structures and alteration that will be vectors to new gold mineralization.
  • The introduction of clean technology field methods and assessment tools to allow geologist to focus exploration on the most prospective ground.

The company intends to follow up Phase 1 with a 100,00m comprehensive drill program to be completed prior to the end of calendar 2019. The Nova Scotia exploration team are some of the most experienced geologists within the Nova Scotia gold districts and they will continue to use modern exploration methods and develop new exploration techniques to better define prospective gold targets.

The Company is well funded and able to execute on its aggressive exploration plans in Nova Scotia, as well as across its broader project portfolio.

Terms

In conjunction with the acquisition, the Company will purchase all of the shares from arm’s-length vendor by issuing 15.5 million common shares of the Company. The vendors shall retain a 2% gross royalty on the project. Finders’ fees of $200,000 in cash and 8% common shares will be paid to qualified arm’s-length parties in connection with the acquisition.

Qualified Person

Mr. Fred Tejada, P.Geo, a Director of the Company, is a Qualified Person under the meaning of Canadian National Instrument 43-101 and is responsible for the technical information contained in this news release.

FOR FURTHER INFORMATION AND ENQUIRIES:

Theo van der Linde
President and CEO
Tel: +1 604-336-3193
Email: tvanderlinde@coronetmetals.com

About Coronet Metals

Coronet Metals Inc. is engaged in the business of acquiring, exploring and developing natural resource properties, with a focus on precious mineral properties/projects which have the potential for both near-term cash flow and significant exploration upside potential.

Forward Looking Information

This news release contains forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

Neither the CSE nor its regulation services provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Corporate Update

Corporate Update

Vancouver, British Columbia (FSCwire)GGX Gold Corp. (TSX.V: GGX) (OTCQB: GGXXF), (FRA; 3SR2) (the “Company” or “GGX”) is pleased to announce that is has arranged a non-brokered private placement of 4 million units at a price of $0.12 per unit for gross proceeds of $480,000. The units of the financing will comprise of one common share and a full share purchase warrant, which may be exercised for a period of three years at a price of $0.15 per share. Directors, officers or other insiders of the Company may participate in the foregoing offerings, and such parties may sell securities of the Company owned or controlled by them personally through the facilities of the TSX Venture Exchange to finance participation in such offerings. The proceeds of the private placement will be used for general working capital and continued exploration work including diamond drilling and trenching at the Company’s Gold Drop property near Greenwood in Southern British Columbia.

A finder’s fee may be paid to eligible finders in accordance to the TSX-V policies. All securities issued pursuant to the offering will be subject to a hold period of four months and one day from the date of closing. The offerings and payment of finders’ fees are both subject to approval by the TSX-V.

On Behalf of the Board of Directors,

Barry Brown, Director

604-488-3900

Investor Relations:

Mr. Jack Singh: 604-488-3900 E-mail: ir@ggxgold.com

“ We don’t have to do this, we get to do this ”

The Crew

To view the graphic in its original size, please click here

Forward Looking Information

This News Release may contain forward-looking statements including but not limited to comments regarding the acquisition of certain mineral claims. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements and Revolver undertakes no obligation to update such statements, except as required by law.

Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates, including that: the current price of and demand for minerals being targeted by the Company will be sustained or will improve; the Company will be able to obtain required exploration licences and other permits; general business and economic conditions will not change in a material adverse manner; financing will be available if and when needed on reasonable terms; the Company will not experience any material accident; and the Company will be able to identify and acquire additional mineral interests on reasonable terms or at all. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including: that resource exploration and development is a speculative business; that environmental laws and regulations may become more onerous; that the Company may not be able to raise additional funds when necessary; fluctuations in currency exchange rates; fluctuating prices of commodities; operating hazards and risks; competition; potential inability to find suitable acquisition opportunities and/or complete the same; and other risks and uncertainties listed in the Company’s public filings. These risks, as well as others, could cause actual results and events to vary significantly. Accordingly, readers should not place undue reliance on forward-looking statements and information, which are qualified in their entirety by this cautionary statement. There can be no assurance that forward-looking information, or the material factors or assumptions used to develop such forward looking information, will prove to be accurate. The Company does not undertake any obligations to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the original release (with media), please click here

Source: GGX Gold Corp. (TSX Venture:GGX, OTCQB:GGXXF, FWB:3SR2)

To follow GGX Gold Corp. on your favorite social media platform or financial websites, please click on the icons below.

Maximum News Dissemination by FSCwire. https://www.fscwire.com

Copyright © 2018 FSCwire

Commander Reports Completion of Consolidation and Closing of Private Placement

Vancouver, British Columbia–(Newsfile Corp. – May 18, 2018) – Commander Resources Ltd. (TSXV: CMD) (“Commander“) reports that, effective at the opening on May 17, 2018, Commander commenced trading on the TSX Venture Exchange on a post one-new for five-old share consolidation basis. Following the share consolidation, Commander had 23,060,514 issued and outstanding shares.

Commander also reports that the non-brokered private placement announced on April 3, 2018 has closed and 12,240,258 Units at a price of $0.17 per Unit (the “Units”) have been issued for gross proceeds of $2,080,843.86. Following completion of the private placement financing, Commander has 35,300,772 issued and outstanding shares.

Each Unit consisted of one common share and one transferable share purchase warrant (a “Warrant”), with each Warrant entitling the holder to purchase one additional common share at a price of $0.25 until May 18, 2020.

Finder’s fees were paid as follows: $38,025.60 and 186,400 Finder’s Warrants to Haywood Securities Inc., $63,033.00 and 308,983 Finder’s Warrants to Sprott Global Resource Investments Ltd., $1,530.00 and 7,500 Finder’s Warrants to Leede Jones Gable Inc. and $3,060.00 and 15,000 Finder’s Warrants to PI Financial Corp. The Finder’s Warrants entitle the holder to purchase one additional common share at a price of $0.25 until May 18, 2020.

Common shares issued in connection with this private placement and issuable upon exercise of Warrants and Finder Warrants are subject to a four-month restricted resale period until September 19, 2018.

The securities have not been and will not be registered under the United States Securities Act of 1933, as amended, (the “U.S. Securities Act“) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined in the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration requirement is available.

About Commander Resources:

Commander Resources is a Canadian focused exploration company that has leveraged its success in exploration through partnerships and sale of properties, while retaining equity and royalty interests. Commander has a portfolio of base and precious metal projects across Canada and significant equity positions in Maritime Resources Corp. and Aston Bay Holdings. Commander also retains royalties from properties that have been partnered, optioned or sold.

On behalf of the Board of Directors

Robert Cameron, P. Geo.
President and CEO

For further information, please call:
Robert Cameron, President and CEO
Toll Free: 1-800-667-7866
info@commanderresources.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Not for dissemination in the United States or through U.S. newswires

BlocPlay Announces Changes in the Board of Directors and Management

Toronto, Ontario–(Newsfile Corp. – May 18, 2018) – BlocPlay Entertainment (CSE: PLAY) (“BlocPlay” or the “Company“) is pleased to announce the appointment of Richard Grieve and Cameron Paddock to the board of directors of the Corporation. Mr. Grieve is also being appointed CEO of the Company.

Mr. Grieve is SVP of Finance and Business Affairs at Bardel Entertainment Inc., a leading animation services provider in North America. Mr. Grieve leads Bardel’s corporate finance and business affairs departments. He is also responsible for aligning the resources of the company with its long-term strategic direction. Mr. Grieve began his career in public accounting working for Ernst & Young LLP, Entertainment & Media Division, providing clients with assurance, tax and business advisory services. Prior to joining Bardel, Mr. Grieve held a senior finance and operations role in a digital media company. Mr. Grieve holds a Bachelor of Commerce (International Business) from the University of Victoria. Mr. Paddock currently manages a family office and serves as a director on various public and private companies in various sectors including cannabis, technology, and mining. Mr. Paddock has extensive knowledge of business development, leadership, corporate governance, and specializing in mergers and acquisitions, recently advising on an acquisition valued in excess of $20M between a private and publicly traded company.

The Corporation also announces that Jon Gill and David Garland have tendered their resignations as directors of the Company. Management and the board of directors would like to thank Messrs. Gill and Garland for their contributions to the Company and wish them well in their future endeavours.

About BlocPlay Entertainment

BlocPlay Entertainment is the world’s first peer-to-peer, de-centralized digital entertainment company. Supporting video gamers, developers, and content creators – worldwide. Each day billions of consumers worldwide enjoy digital entertainment products. BlocPlay Entertainment plans to deliver a fully transparent distribution, publishing, and marketing platform for videogames and eSports events through our innovative tokenization system known as Token Play. BlocPlay Entertainment develops, licences and markets digital entertainment technologies across multiple platforms.

About TokenPlay

TokenPlay is a wholly owned subsidiary of BlocPlay Entertainment and is the customer facing Brand involved in the development and utilization of blockchain technology in the video game space, which will seek to provide a platform for the exchange of in-game currencies and tokens.

For further information, please contact:

Richard Grieve
BlocPlay Entertainment Inc.
Tel: 1-888-449-4148
Email: investors@blocplays.com

Forward-Looking Information

Certain information set forth in this news release may contain forward-looking information that involve substantial known and unknown risks and uncertainties. This forward-looking information is subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, the impact of general economic conditions, industry conditions, failure to enter into a definitive agreement and complete the Acquisition, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking information. The parties undertake no obligation to update forward-looking information except as otherwise may be required by applicable securities law.

Canada’s Island Garden Begins CAD$35 Million Expansion in Prince Edward Island to Support Launch of New FIGR Brand

By Canadas Island Garden Inc.

Premium Quality Cannabis Company to Create Between 100 and 200 Jobs by 2020

CHARLOTTETOWN, CANADA / ACCESSWIRE / MAY 18, 2018 / Canada’s Island Garden today unveiled a new FIGR brand, which reflects the scientific rigor and decades of agronomic excellence for which the Company is known.

Since the acquisition of 75 percent of Canada’s Island Garden by Canadian Cultivated Products, a wholly owned indirect subsidiary of Alliance One International, the companies have been working on a new naming and branding concept. Canadian Cultivated Products will be rebranded to FIGR Cannabis, Canada’s Island Garden to FIGR East and Goldleaf Pharm, a sister company in Simcoe, Ontario, to FIGR Norfolk.

“Our Company has always believed that creativity can figure out almost anything. Our new FIGR brand represents our Company’s efforts to provide products of a consistent quality that are handcrafted with unconventional thinking” said Edwin Jewell, president of Canada’s Island Garden. “We pride ourselves on the unique combination of generations of horticulture excellence and modern agricultural practices to create high-quality products which customers can trust and enjoy.”

FIGR products will become available to the public in Canada as soon as sales for the recreational adult market are legalized. Sales to medical patients in Canada will remain under the current branding of Canada’s Island Garden.

The new brand was announced at the groundbreaking of FIGR’s significant expansion in Prince Edward Island. Phase 1 of the expansion, which includes a 166,000-square-foot greenhouse and 54,000-square-foot warehouse, is a CAD$35 million investment. The warehouse is being constructed to also accommodate Phase 2 of the expansion, which would add an additional 90,000 square feet of greenhouse space. Phase 1 will increase the facility’s annual production capacity to 18,000 kilograms. Upon completion of Phase 2, FIGR is anticipated to have an annual production capacity in excess of 35,000 kilograms.

“Our new state-of-the-art facilities will allow us to cultivate cannabis that consistently meets and exceeds legal requirements and Canadian consumers’ desires for a premium cannabis brand. With additional capacity, we are committed to taking PEI premium-grown, hand-crafted cannabis across Canada and, over time as legal markets develop, worldwide,” said Jewell. “As the Canadian cannabis market opens up, we are proud to offer PEI residents product that is produced by their fellow Islanders. These new facilities will offer full-time, year-round employment for Islanders.”

Both facilities will feature the latest technological advancements in horticulture and cannabis production to allow for the production of a high-quality and sustainable product for consumers. The facilities will be optimized to create comprehensive transparency and traceability from plant to final product and include security protections to maintain proper control of the facility.

The new greenhouse will provide an additional controlled environment for planting, growing and harvesting the plant as well as space for research and development where the company can continue to improve crop quality. Irrigation and environmental conditions will be monitored and controlled by specialty systems to maximize yield, and sunlight and natural ventilation will help reduce production costs while maintaining a high-quality product.

The warehouse, which was designed specifically for smooth cannabis production and processing, will provide space for trimming, drying, packaging, oil extraction, propagation of cuttings and storage of finished product. In addition, it will house FIGR’s administrative staff offices.

The greenhouse and warehouse, which are the first step in a greater expansion plan, are anticipated to be operational by spring 2019. FIGR expects to create between 100 and 200 jobs over the course of the next three years.

Alliance One International is an agricultural company that delivers value-added products and services to businesses and customers and is a trusted provider of responsibly sourced, independently verified, sustainable and traceable products, ingredients and services. AOI’s indirect stake in Canada’s Island Garden is one step in its journey to broaden its business portfolio by focusing on consumer-driven agricultural products.

About Canada’s Island Garden

Based in Charlottetown, Prince Edward Island, Canada’s Island Garden is Prince Edward Island’s only federally licensed producer of cannabis. In January 2018, the Company announced a supply agreement with the Province of Prince Edward Island to provide a high-quality supply of cannabis to Islanders. For more information, visit www.canadasislandgarden.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. Such statements include, but are not limited to, statements about future plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based on the current beliefs and expectations of management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results may differ materially from those currently anticipated expected or projected. The following factors, among others, could cause actual results to differ from those expressed or implied by the forward-looking statements: the impact of regulation and litigation and risks and uncertainties associated with the expansion of the FIGR brand, including the risk of obtaining anticipated regulatory approvals in Canada, as well as the anticipation of enactment of Canadian legislation legalizing the production and sale of cannabis for adult recreational use and potential relaxation of restrictions prohibiting medical or adult recreational use of Cannabis in other jurisdictions.

Media Contact:

Edwin Jewell
Canada’s Island Garden
(902) 628-7129

SOURCE: Canada’s Island Garden Inc.

ReleaseID: 500284

Jaguar Health, Inc. Reports First-Quarter 2018 Operational Updates and Voting Results from 2018 Annual Meeting of Stockholders

By Jaguar Health, Inc.

Company Management to Host Conference Call Monday, May 21st at 4:30 p.m. Eastern Time for Investors and Analysts

SAN FRANCISCO, CA / ACCESSWIRE / May 18, 2018 / Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company filed on May 15, 2018 its first quarter report on Form 10-Q with the U.S. Securities and Exchange Commission (SEC). The Company also today announced voting results from Jaguar’s 2018 Annual Meeting of Stockholders, which was held earlier today. Additionally, Jaguar announced today that Company management is hosting a conference call on Monday, May 21st at 4:30 p.m. Eastern Time for investors and analysts. Dial-in information for the call appears below, along with instructions for accessing the replay of the call.

Financial Highlights
(In thousands except for per share amounts and percentages) Q1 18 Q1 17 % Change
Gross product sales $ 839 $ 75 1,019
Net product revenue $ 627 $ 75 736
Collaboration income $ 177 $ 748 (76)
Net loss per share attributed to common shareholder $(6,691) $(4,715) (42)
Net loss per share $(0.05) $(0.33) 85

First-Quarter 2018 and Recent Company Highlights

The key highlight of Q1 2018 is the completion of Jaguar’s recent round of financing. As the Company announced on March 26, 2018, Jaguar has closed on separate private placements involving an aggregate of approximately $14.2 million in gross proceeds. The Company anticipates being able to sell up to an additional $2.5 million of the Company’s voting common stock (“Common Stock”) to certain investors on or before June 30, 2018. In the larger private placement of shares of the Company’s Series A Convertible Participating Preferred Stock, Sagard Capital Partners, L.P. (“Sagard”), an entity associated with Sagard Holdings ULC (“Sagard Holdings”), is the investor. The other private placement involved the issuance of Common Stock to other investors. As a result of this financing, Jaguar is now able to engage in a broad range of commercialization efforts for Mytesi®, and the Company believes its corresponding spending is commensurate with the requirements for the commercial launch of a specialty pharmaceutical product.

  • Salesforce Expansion: Throughout the fourth quarter of 2017, Napo Pharmaceuticals, Inc. (Napo), Jaguar’s wholly-owned human health subsidiary, deployed 9 sales representatives to promote Mytesi® to doctors who are frequent prescribers of antiretrovirals (ARVs), and the Company now has 17 dedicated, highly experienced Mytesi® sales representatives in addition to a national sales director, a regional business director, and a telesales representative. Napo’s salesforce is focused on targeting the right doctors – HIV specialists who are high prescribers of ARVs and gastroenterologists who see large populations of people living with HIV (PLWH), and is strategically positioned to cover the U.S. geographies with the highest potential, including the following key regions: San Francisco, Los Angeles/Palm Springs, Miami/southern Florida, northern Florida, New York, New Jersey, Pennsylvania, Delaware, Maryland, DC, Houston, northern Texas, Chicago, St. Louis, Indianapolis, Kansas City, Alabama, Mississippi, Louisiana, North Carolina/South Carolina and Atlanta. Areas not accessible by direct sales representation are able to be reached with Napo’s telesales representative.
  • Positive Sales Trends: Shipments of Mytesi® to retailers grew 11.65 percent in Q1 2018 compared to Q4 2017; the total number of Mytesi® prescribers grew 8.43 percent from Q4 2017 to Q1 2018; and the total number of Mytesi® prescriptions increased 6.26% percent in Q1 2018 compared to Q4 2017. During this same period, redemptions of Mytesi® copay coupons increased 153.85 percent quarter over quarter.
  • Human Pipeline: The Company’s goals for 2018 include the allocation of resources in support of the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Mytesi® for the indication of cancer therapy-related diarrhea (CTD), and initiating discussions with FDA regarding a possible Special Protocol Assessment (SPA). As previously announced, Napo has received orphan-drug designation from the FDA for crofelemer for the treatment of short bowel syndrome (SBS). The Company is supporting the development of a formulation of crofelemer to support an investigator-initiated trial of crofelemer at Sheikh Khalifa Medical City in Abu Dhabi for use in children with a disease known as congenital and diarrheal disorder (CDD). CDD is a group of rare chronic intestinal channel diseases that occur exclusively in early infancy and are characterized by severe lifelong diarrhea and a need for nutritional intake either parenterally or with a feeding tube. This congenital disorder is much more prevalent in the MENA region than the U.S., facilitating patient recruitment. The Company’s goals for 2018 also include additional animal work to support the orphan-drug application for CDD. An additional key pipeline goal includes the formulation and regulatory activities to support an IND application for lechlemer, Jaguar’s second-generation anti-secretory botanical drug product candidate for the indication of cholera, as well as efforts to pursue obtaining a priority review voucher from FDA for the possible cholera indication. Cholera has received designation by the FDA for a potential tropical disease priority review voucher upon approval for the first indication for a product. These vouchers have sold for $110 million to $350 million, and provide sponsors with an incentive to develop products for important lifesaving medicines that are needed primarily in resource-constrained regions of the world. Cholera is an acute diarrheal illness that kills thousands of people worldwide each year due to rapid dehydration in the first 2 -18 hours after infection. According to CNN, the number of suspected cholera cases in Yemen hit 1 million by December 21, 2017, following the detection, in April 2017, of the outbreak, which is the world’s biggest cholera outbreak in recorded history. The epidemic has already killed more than 2,000 people.

Commercial, Educational and Promotional Activities to Support Mytesi® Awareness and Sales

As a result of the recent financing referenced above, the Company believes it is now able to initiate funding of the following collection of commercial, educational, and promotional activities to support Mytesi® awareness and sales.

  • Napo Speakers Bureau: Napo has completed the training of 39 healthcare practitioners and 14 patient advocates to serve as members of the Napo Speakers Bureau. During the first quarter of 2018, the Company conducted 64 Mytesi® speaker programs.
  • Regional Advisory Board Meetings: During the first quarter of 2018, the Company conducted two Regional Advisory Board meetings on Mytesi® with healthcare professionals regarding treatment of HIV-related diarrhea, and six additional Regional Advisory Boards meetings have been conducted in April and May 2018.
  • Exhibits & Event Sponsorships: Napo plans to exhibit at, sponsor, or speak at approximately 32 national, international and regional health-related conferences or special events in 2018. Seven of these events took place in the first quarter of 2018, and, on May 20, 2018, Napo will be promoting Mytesi® at an exhibit at AIDS Walk New York in New York City’s Central Park.
  • “Under Pressure” Episode of Merce Uses Comedy to Help PLWH Talk About Diarrhea: As announced May 15, 2018, the Company is supporting production of Merce, an award-winning musical comedy web series about an HIV-positive man living in New York City. A special short episode called ”Under Pressure” has been produced by the Merce team that Napo will use in its awareness campaign. View the episode at http://enoughdiarrhea.com/video.html.
  • From the standpoint of education and awareness, the two recent articles listed below illustrate that Mytesi® is highly relevant to the PLWH community:
    • Experts Highlight that Immune System Activation in Aging Patients Living with HIV/AIDS Triggers Effects Such as “Leaky Gut”, Which Can Lead to Diarrhea: A recently published article in The Washington Post substantiates that, even with suppression of the HIV virus with ARVs, PLWH experience a long period of immune system activation, which, as these individuals age, triggers effects such as “leaky gut”, causing chronic inflammation which can lead to diarrhea.
    • Prevalence of Diarrhea in HIV+ Women: An article recently published in the Journal of Acquired Immune Deficiency Syndrome titled “Use of Nonantiretroviral Medications That May Impact Neurocognition: Patterns and Predictors in a Large, Long-Term HIV Cohort Study” looked at use of concomitant non-ART medications for comorbidities in HIV+ women. The study’s authors, who were specifically looking at non-ART medicines associated with neurocognitive adverse events, found that HIV+ women in the study were twice as likely to be on a GI medication as non-HIV+ women, providing further evidence of the continuing prevalence of diarrhea in PLWH.
  • NapoCares Patient Assistance Program: Napo is addressing the reimbursement environment through this program, which provides access to a copay savings card intended to help facilitate that patients may never have to pay more than $25 a month to fill a Mytesi® prescription.
  • Agreement with Transition Patient Services (TPS): In March 2018, as previously announced, Napo signed an agreement with pharmacy services provider TPS to operate a nationwide pilot program for Mytesi®. Core program benefits include ensuring patient out-of-pocket expenses for Mytesi® are as low as possible, and improving Mytesi® refill adherence through transmission of renewal reminders to patients.
  • Agreement with ADAP Crisis Task Force: As announced April 10, 2018, Napo signed an agreement with the ADAP Crisis Task Force. ADAPs provide life-saving HIV treatments to more than half a million low income, uninsured, and underinsured PLWH. Mytesi® was added to the Texas, Maryland, Pennsylvania and Delaware ADAPs in April 2018, and is currently on the ADAP formulary in 23 states.
  • Animal R&D and Commercial Activities: Research and development efforts related to animal products in 2018 will be limited to only the Company’s plan to support the completion of the Minor Use in a Minor Species (MUMS) new animal drug application filings with FDA for chemotherapy-induced diarrhea (CID) in dogs and exercise-induced diarrhea (EID) in dogs. Equilevia, Jaguar’s non-prescription, personalized, premium product for total gut health in equine athletes, is produced in response to individual orders from customers, which keeps commercial expenses for the product at a minimum.

First-Quarter 2018 Total Company Financial Results

  • Total Net Product Revenue: Gross sales in the first quarter of 2018 were $839 thousand, and net sales were $627 thousand, an increase of 1,019 percent and 736 percent of gross and net sales, respectively, over the first quarter of 2017. This was driven by the merger of Napo and Jaguar Animal Health, Inc., which became effective July 31, 2017, which resulted in Jaguar Health now reporting both human health and animal health segments and revenue. Human product revenue in the first quarter of 2018 included Mytesi® gross sales of $795 thousand, resulting in Mytesi® net sales of $584 thousand. Animal health sales consisted of $44 thousand gross and net sales of Neonorm. In the first quarter of 2017, animal health product revenue consisted of $45 thousand gross and net sales of Neonorm and $30 thousand in sales of botanical extract. There was no human health product revenue in the first quarter of 2017, because the merger was not effective until July 31, 2017.
  • Total Collaboration Income: Collaboration revenue stems from the animal health collaboration the Company entered into in January 2017. As previously reported, the collaboration was terminated on January 30, 2018 and Jaguar has regained global commercial rights to all companion animal indications for Canalevia, consisting of the same active pharmaceutical ingredient, crofelemer, as Mytesi®. The collaboration revenue recognized in the first quarter of 2018 represents the final recognition of the amortization of the $2.5 million milestone received upon the signing of the collaboration. The collaboration revenue in the first quarter of 2017 includes expense reimbursement, as well as milestone payment recognition.
  • Operating Expenses: The total operating expense for the quarter ended March 31, 2018 was $5.9 million. The human health segment operating expense was $3.5 million and the animal health segment operating expense was $2.4 million. The operating expense for the quarter ended March 31, 2017 was $4.7 million, which was all animal health segment operating expense. The 26 percent increase in total operating expense quarter over quarter is due to commercial activities associated with Mytesi®, which can be compared to the 736 percent increase (referenced above under “Total Net Product Revenue”) in total revenue quarter over quarter. The operating expense decrease of $2.3 million for the animal health segment for the first quarter of 2017 compared to the first quarter of 2018 is due to the Company’s resources being reallocated to the launch and commercial operations of Mytesi®.
    • The R&D expense was $758 thousand for the quarter ended March 31, 2018 compared to $1.3 million for the quarter ended March 31, 2017. The human health segment incurred expenses of $313 thousand for the quarter ended March 31, 2018 and the animal segment incurred expenses of $445 thousand in the same quarter. The total R&D expense for the quarter ended March 31, 2017 consisted of animal health clinical trials and regulatory expenses for the development of Canalevia for CID in dogs. The 40% decrease of R&D expenses quarter over quarter illustrates the transition of Jaguar Health from an R&D company into a commercial stage human health product company with a pharmaceutical pipeline of crofelemer follow-on indications and related products in place for future opportunity and growth.
    • The sales and marketing expense for the quarter ended March 31, 2018 was $1.70 million as compared to $123 thousand for the quarter ended March 31, 2017. The $1.6 million increase represents approximately a $1.0 million Mytesi® promotional spend and a $600 thousand increase in spend on the formation of a salesforce and commercial resources for the commercial operations of Mytesi®.
    • The general and administrative expense for the quarter ended March 31, 2018 totaled $3.0 million compared to $3.3 million for the quarter ended March 31, 2017, a 10% decrease quarter over quarter. The G&A spend of $1.1 million for the quarter ended March 31, 2018 consisted of building G&A support functions for the human commercial entity such as audit, legal, accounting, human resources, IT, public company expense, and facilities. Additional quarterly expenses of $1.9 million consisted of audit, legal, public company expenses and outside services to facilitate debt refinancing and the new equity investment of Sagard Capital Partners, LP and other investors, which facilitated the Company in reducing $4.7 million of debt and payables incurred during the 2017 Jaguar Health and Napo merger preparation and transaction. The general and administrative expense for the quarter ended March 31, 2017 of $3.3 million was mainly attributable to Jaguar’s due diligence and preparation for the merger with Napo.
  • Income Tax Rate: The forecasted effective tax rate for the three months ended March 31, 2018 and 2017 was zero percent, primarily as a result of the estimated tax loss for the year and the change in valuation allowance.
  • Net loss per share attributable to common shareholders: For the first quarter of 2018, net loss was $6.7 million, compared to $4.7 million in the first quarter of 2017. Net loss and comprehensive loss for Q1 2018 was $5.7 million. As a result of the Sagard Capital LC premium priced stock purchase transaction in March 2018, the Company recorded a deemed dividend charge of $995 thousand for the accretion of the discount on the Series A shares issued. The deemed dividend was a non-cash transaction and is reflected below net loss to arrive at net loss available to common stockholders on the Company’s condensed consolidated statement of operations for the three months ended March 31, 2018.
  • Earnings (Loss) per Share: In the first quarter of 2018, diluted loss per share was ($0.05); in the first quarter of 2017, diluted loss per share was ($0.33), representing an 85% improvement in 2018.
  • Cash and Cash Equivalents: As of March 31, 2018, Jaguar Health had $7.8 million of cash and cash equivalents compared to $521 thousand as of December 31, 2017. During the first quarter of 2018, the Company used $9.6 million in operating cash flow, including the reduction in debt and accounts payable resulting from the merger transaction of $4.7 million, and provided $16.7 million in investment activities.
  • Expectation of Increased Sales and Marketing Expenses in the Coming Quarters: The Company expects increased sales and marketing expenses in the coming quarters, as Napo now has a nearly complete commercial team in place. As sales volumes increase, Jaguar hopes to take advantage of the economies of scale opportunity to bring down expenses associated with the manufacturing, supply, and distribution of Mytesi®.

Voting Results from Jaguar’s 2018 Annual Meeting of Stockholders

Jaguar held its 2018 Annual Meeting of Stockholders of the Company on May 18, 2018. Four proposals were submitted to and approved by the stockholders of the Company. The proposals are described in detail in the Company’s Proxy Statement. The final results for the votes regarding each proposal are set forth below.

  1. Stockholders ratified the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2018. The votes regarding this proposal were as follows:

For Against Abstain Broker Non-Votes Uncast
127,018,513 1,209,598 2,916,143 0 0

  1. Stockholders approved, for purposes of Nasdaq Rule 5635(b), the removal of the 19.99% Limitation with respect to the as-converted voting rights and conversion of the Company’s Series A Convertible Participating Preferred Stock into shares of the Company’s Common Stock. The votes regarding this proposal were as follows:

For Against Abstain Broker Non-Votes Uncast
61,913,931 2,017,386 5,749,731 29,380,580 32,082,626

  1. Stockholders approved the adoption of an amendment to the Company’s Third Amended and Restated Certificate of Incorporation (the “COI”) to effect a reverse stock split of the Company’s issued and outstanding Common Stock at a ratio not less than 1-for-11 and not greater than 1-for-15, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before June 30, 2018 without further approval or authorization of the Company’s stockholders (the “Reverse Stock Split”). The votes regarding this proposal were as follows:

For Against Abstain Broker Non-Votes Uncast
122,174,162 8,560,249 409,843 0 0

  1. Stockholders approved the adoption of an amendment to the COI to decrease the number of authorized shares of Common Stock to 150,000,000 shares, contingent upon the Reverse Stock Split in Proposal 3 being approved and effected. The votes regarding this proposal were as follows:

For Against Abstain Broker Non-Votes Uncast
125,598,730 4,319,948 1,225,576 0 0

Reverse Split of Jaguar Stock and Compliance with Nasdaq’s Listing Standards

On May 14, 2018, Jaguar’s Board of Directors voted in favor of effecting a reverse split of the Company’s issued and outstanding Common Stock, at a ratio of 1-for-15, in order to support the Company’s compliance with Nasdaq’s listing standards.

Conference Call Dial-In Instructions

Investors interested in listening to the live call should dial 800-239-9838 (U.S. Toll Free), 323-794-2551 (International). Please ask the operator to connect you to the call or provide the conference ID number: 8098669. A live webcast of the conference call will be available online which can be accessed on the investor relations section of the Jaguar website (click here). Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

For interested individuals unable to join the conference call, a replay of the webcast will be available on the investor relations section of Jaguar’s website (click here) for 90 days following the call. Also, a dial-in replay of the call will be available through June 4, 2018, at 844-512-2921 (U.S. Toll Free) or 412-317-6671 (International). Participants must use the following code to access the dial-in replay of the call: 8098669.

Mytesi®

Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

About Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding expected increases in sales and marketing expenses and sales volume, the Company’s plan to bring down expenses associated with the manufacturing, supply, and distribution of Mytesi®, and the Company’s plan to expand the Mytesi® salesforce to 20 reps and an additional sales manager in 2018. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

ReleaseID: 500280

West Red Lake Gold Exploration Program Update – May 2018

West Red Lake Gold Exploration Program Update – May 2018

Toronto, Ontario (FSCwire) – West Red Lake Gold Mines Inc. (“West Red Lake Gold” or the “Company”) (CSE: RLG) (FSE: HYK) (OTCQB: RLGMF) announces a deep hole has been drilled on the Rowan Mine property as part of ongoing exploration work on the 3,100 hectare West Red Lake Project located in the prolific Red Lake Gold District, Northwestern Ontario, Canada.

The hole, which was located 450m east of the Rowan Mine Shaft, was drilled to the north at -74 degrees over a length of 1,272m. Due to spring breakup conditions drilling operations were stopped and further drilling is planned to commerce in the second half of 2018.

The drill core has been logged and samples have been sent out for assay.

Mr. John Kontak, President of West Red Lake Gold Mines stated, “We are very pleased to be continuing our exploration programs on the promising Red Lake property throughout 2018 and look forward to further property developments.”

The Rowan Mine Zones lie within the east-west trending regional shear structure known as the Pipestone Bay St Paul Deformation Zone (the “PBS Zone”) which is a regional geological structure that crosses the Company property and continues east to the town of Red Lake. Gold zones are hosted within a sequence of hydrothermally altered mafic volcanics with intercalatedfelsic volcanics and porphyries as well as ultramafics. Two distinct gold mineralization styles are noted: one associated with sulphide mineralization and the other with smoky quartz veins and fine grained native gold. The mineralization is hosted within a shear zone up to a hundred metres wide.

The Company property is situated on the Red Lake Archean Greenstone Belt which hosts the high grade gold mines of the Red Lake Gold District. Three former gold mines on the West Red Lake Project property are situated on the PBS Zone with the Mount Jamie Mine located in the western portion of the West Red Lake Project, the Rowan Mine in the central portion and the Red Summit Mine located in the eastern portion. The regional scale Golden Arm Structure and the sub-parallel NT Zone cross onto the West Red Lake Project from the south boundary and trend northeast for 2 km to where they merge and intersect with the PBS Zone at a location situated between the Rowan Mine and the Red Summit Mine (the “Structural Intersection”).

Twenty kilometres to the east of the Company property a similar geologically important intersection of two regional gold bearing structures occurs proximal to the world class Red Lake Mine and Campbell Mine, providing a highly favourable geological model believed to be similar to that seen at the Structural Intersection and illustrating the significant exploration potential for high grade gold zones on the Company’s West Red Lake Project.

The Company also announces that it has approved the issuance of 639,000 common shares at a deemed price of $0.125 per share for services rendered to the Company by several providers.

Technical Information

The technical information presented in this news release has been reviewed and approved by Kenneth Guy, P.Geo., a consultant to West Red Lake Gold and the Qualified Person for exploration at the West Red Lake Project, as defined by National Instrument 43-101 “Standards of Disclosure for Mineral Projects” (“NI 43-101”).

West Red Lake Gold Mines Inc. is a Toronto-based minerals exploration company focused on gold exploration and development in the prolific Red Lake Gold District of Northwest Ontario, Canada. The Red Lake Gold District is host to some of the richest gold deposits in the world and has produced 30 million ounces of gold from high grade zones. The Company has assembled a significant property position totalling 3100 hectares in west Red Lake (the “West Red Lake Project”) which contains three former gold mines. The Mount Jamie Mine and Red Summit Mine properties are 100% owned by the Company and the Rowan Mine property is held in a 60%-owned joint venture with Red Lake Gold Mines, a partnership of Goldcorp Inc. and Goldcorp Canada Ltd. The West Red Lake Project property covers a 12 kilometre strike length along the Pipestone Bay St Paul Deformation Zone and the Company plans to continue to explore the property both along strike and to depth. To find out more about West Red Lake Gold Mines, please visit our website at http://www.westredlakegold.com.

For more information, please contact: John Kontak, President Phone: 416-203-9181 Email: jkontak@rlgold.ca

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release. Certain statements contained in this news release constitute “forward looking statements”. When used in this document, the words “anticipated”, “expect”, “estimated”, “forecast”, “planned”, and similar expressions are intended to identify forward looking statements or information. These statements are based on current expectations of management, however, they are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from the forward-looking statements in this news release. Readers are cautioned not to place undue reliance on these statements. West Red Lake Gold does not undertake any obligation to revise or update any forward- looking statements as a result of new information, future events or otherwise after the date hereof, except as required by securities laws.

To view the original release (with media), please click here

Source: West Red Lake Gold Mines Inc (CSE:RLG, OTCQB:RLGMF, OTC Bulletin Board:HYLKF)

To follow West Red Lake Gold Mines Inc on your favorite social media platform or financial websites, please click on the icons below.

Maximum News Dissemination by FSCwire. https://www.fscwire.com

Copyright © 2018 FSCwire

FP Newspapers Inc. Reports Results of Annual General Meeting of Shareholders

FP Newspapers Inc. Reports Results of Annual General Meeting of Shareholders

Winnipeg, Manitoba (FSCwire) – FP Newspapers Inc. (“FPI”) announces that all resolutions presented at the Corporation’s annual general meeting held on May 18, 2018 were approved by the shareholders, including the special resolution to amend the Articles of the Corporation to increase the maximum number of directors from five to six and the election of the directors nominated by management. The proxy results on the election of directors were as follows:

Name of Nominee

Votes For

Votes Withheld

Phil de Montmollin

2,383,255 (99.24%)

18,316 (0.76%)

Stephen Dembroski

2,381,035 (99.14%)

20,536 (0.86%)

Harvey Secter

2,379,635 (99.09%)

21,936 (0.91%)

Aldo Santin

2,369,955 (98.68%)

31,616 (1.32%)

Phil de Montmollin (as the Corporation’s nominee as a director of FPCN General Partner Inc.)

2,382,505 (99.21%)

19,066 (0.79%)

Stephen Dembroski (as the Corporation’s nominee as a director of FPCN General Partner Inc.)

2,384,705 (99.30%)

16,866 (0.70%)

Harvey Secter (as the Corporation’s nominee as a director of FPCN General Partner Inc.)

2,384,205 (99.28%)

17,366 (0.72%)

Ronald Stern, who serves as Chairman of the Corporation, and Robert Silver were also re-elected as directors of the Corporation by FPCN Media Management Inc. pursuant to its rights as the holder of preferred shares.

Shareholders also passed an ordinary resolution approving the appointment of PricewaterhouseCoopers LLP as auditors for the ensuing year.

About FPI

FPI owns securities entitling it to 49% of the distributable cash of FP Canadian Newspapers Limited Partnership (“FPLP”). FPLP owns the Winnipeg Free Press, the Brandon Sun, and their related businesses, as well as the Canstar Community News division, the publisher of six community newspapers in the Winnipeg region, The Carillon in Steinbach with its related commercial printing operations and the Carberry News Express weekly publication. The Winnipeg Free Press publishes six days a week for delivery to subscribers and single copy sales, and publishes a single copy edition on Sundays. Vividata, a third party research firm, which measures newspaper readership across Canadian markets, estimates that weekly 78% of all Winnipeg adults read the print or digital edition of the Winnipeg Free Press. The Brandon Sun publishes six days a week, serving the region with an average circulation of approximately 10,500 copies. Canstar Community News publishes weekly with an average circulation of approximately 200,000 copies. The businesses employ approximately 410 full-time equivalent people in Winnipeg, Brandon, Steinbach and Carberry, Manitoba. Further information can be found at www.fpnewspapers.com and in disclosure documents filed by FP Newspapers Inc. with the securities regulatory authorities, available at www.sedar.com.

For further information please contact:

Daniel Koshowski, CFO

FP Newspapers Inc.

Phone (204) 771-1897

To view the original release, please click

Maximum News Dissemination by FSCwire. https://www.fscwire.com

Copyright © 2018 FSCwire

DEADLINE ALERT: The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Facebook, Inc. Shareholders and a Lead Plaintiff Deadline of May 21, 2018 (FB)

By The Klein Law Firm

NEW YORK, NY / ACCESSWIRE / May 18, 2018 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Facebook, Inc. (NASDAQ: FB) who purchased shares between February 3, 2017 and March 19, 2018. The action, which was filed in the United States District Court for the Northern District of California, alleges that the Company violated federal securities laws.

In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) Facebook violated its own purported data privacy policies by allowing third parties to access the personal data of millions of Facebook users without the users’ consent; (ii) discovery of the foregoing conduct would foreseeably subject the Company to heightened regulatory scrutiny; and (iii) as a result, Facebook’s public statements were materially false and misleading at all relevant times.

Shareholders have until May 21, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-c/facebook-inc-2?wire=1.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Joseph Klein, Esq.
Empire State Building|
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 500270

Tuxis Corporation Announces 2017 Financial Results

By Tuxis Corporation

NEW YORK, NY / ACCESSWIRE / May 18, 2018 / Tuxis Corporation (OTC PINK: TUXS) (the “Company”) today reported its financial results for the year ended December 31, 2017.

The Company recorded a net loss of $560,848 or $0.46 per share for the year ended December 31, 2017 compared to net income of $2,534,697 or $2.07 per share for the year ended December 31, 2016, which included a gain of $2,945,030 on the sale of its self storage and other properties.

The Company’s book value per share at December 31, 2017 was $6.32 (shareholders’ equity of $7,667,465 divided by 1,213,487 shares issued and outstanding).

The Company’s unaudited balance sheets, statements of comprehensive income (loss), and statements of cash flows as of and for the year ended December 31, 2017, including a reconciliation of net loss to adjusted EBITDA, are appended to the copy of this press release on www.tuxis.com.

About Tuxis Corporation

Tuxis Corporation is a holding company that engages through subsidiaries primarily in real estate development and management. To learn more about Tuxis Corporation, including Rule 15c2-11 information, please visit www.tuxis.com.

Cautionary Note Regarding Forward Looking Statements

Certain information presented in this press release may contain “forward-looking statements” within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward looking statements include statements concerning the Company’s plans, including its plans as to the use of the proceeds from the sale, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, and other information that is not historical information. In some cases, forward looking statements can be identified by terminology such as “believes,” “expects,” “estimates,” “may,” “will,” “should,” “anticipates” or “intends,” or the negative of such terms or other comparable terminology, or by discussions of strategy. All forward-looking statements by the Company involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company, which may cause the Company’s actual results to be materially different from those expressed or implied by such statements. The Company may also make additional forward looking statements from time to time. All such subsequent forward-looking statements, whether written or oral, by the Company or on its behalf, are also expressly qualified by these cautionary statements. All forward-looking statements, including without limitation, the Company’s examination of historical operating trends and estimates of future earnings, are based upon the Company’s current expectations and various assumptions. There can be no assurance that the Company’s expectations, beliefs and projections will result or be achieved. All forward looking statements apply only as of the date made. The Company undertakes no obligation to publicly update or revise forward looking statements which may be made to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events.

The Company views book value per share, a non-GAAP financial measure, as an important indicator of financial performance. Presented in conjunction with other financial information, the combined presentation can enhance an investor’s understanding of the Company’s underlying financial condition and results from operations. The definition of book value as presented in this press release is shareholders’ equity divided by currently issued and outstanding shares.

Contact:

Thomas O’Malley
Chief Financial Officer
1-212-785-0900, ext. 267
tomalley@tuxis.com
www.tuxis.com

SOURCE: Tuxis Corporation

ReleaseID: 500261